About The Study: High-dose influenza vaccine elicited a more robust humoral response in patients with heart failure or prior myocardial infarction enrolled in the INVESTED randomized clinical trial, with no association between seroconversion status and the risk for cardiopulmonary hospitalizations or all-cause mortality. Vaccination to prevent influenza remains critical in high-risk populations.
Authors: Scott D. Solomon, M.D., of Brigham and Women's Hospital and Harvard Medical School in Boston, and Orly Vardeny, Pharm.D., M.S., of the University of Minnesota in Minneapolis, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.0468)
